Multidisciplinary | Nano Publications https://bibliography.nanobiotix.com Navigate through all Nanobiotix publications online Tue, 24 May 2022 15:49:26 +0000 en-US hourly 1 https://wordpress.org/?v=6.0 https://bibliography.nanobiotix.com/wp-content/uploads/2019/11/cropped-n-icon-512x512-32x32.png Multidisciplinary | Nano Publications https://bibliography.nanobiotix.com 32 32 2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial https://bibliography.nanobiotix.com/2018-aso-nbtxr3-in-the-treatment-of-liver-cancer-a-phase-i-ii-trial/ Thu, 02 Aug 2018 08:56:03 +0000 http://bibliography.nanobiotix.com/?p=1510 With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

The post 2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial first appeared on Nano Publications.]]>

Authors

Chajon E.1, Pracht M.1, de Baere T.2, Nguyen F.2, Bronowicki J.P.3, Vendrely V.4, Baumann A.S.5, Croisé-Laurent V.3, Rio E.6, Rolland Y.1, Le Sourd S.1

1 – Radiation Oncology, Centre Eugene – Marquis, Rennes, France
2 – Radiation oncology, Institut Gustave Roussy, Villejuif, France
3 – Hepatology and Gastroenterology, Hôpital de Brabois, Vandoeuvre Les Nancy, France
4 – Radiotherapy, Groupe Hospitalier Sud – Hôpital Haut-Lévêque, Pessac, France
5 – Radiotherapy, Institut de Cancérologie de Lorraine, Nancy, France
6 – Radiotherapy, Institut de cancérologie de l’Ouest, Nantes, France

Summary

Hepatocellular carcinoma (HCC) is the most widespread primary liver cancer. Liver metastasis (mets) are even more common with a wide range of malignancies. Management of both liver affections is a challenging task regarding toxicity toward liver functions. In response, NBTXR3, innovative injectable hafnium oxide nanoparticles activated by radiotherapy, was developed to increase the local deposit of energy within the tumor cells without negatively affecting the liver. It is currently evaluated in a phase I/II clinical trial to introduce the use of NBTXR3 with stereotactic body radiation therapy (SBRT) in patients with HCC or liver mets [NCT02721056].

Overall, current results observed a safe and well tolerated profile for NBTXR3 indicating an encouraging perspective in patients highly vulnerable to liver complications. This multidisciplinary study brought together the successful complex cooperation of several centers and of different medical disciplines to treat two types of liver affections with an innovative approach.

The post 2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial first appeared on Nano Publications.]]> 2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers https://bibliography.nanobiotix.com/2018-asco-gi-a-phase-i-ii-trial-of-nbtxr3-nanoparticles-activated-by-sbrt-in-the-treatment-of-liver-cancers/ https://bibliography.nanobiotix.com/2018-asco-gi-a-phase-i-ii-trial-of-nbtxr3-nanoparticles-activated-by-sbrt-in-the-treatment-of-liver-cancers/#respond Thu, 24 May 2018 15:24:56 +0000 http://bibliography.nanobiotix.com/?p=1413 The physical mode of action of NBTXR3 may represent a breakthrough approach for the local treatment of liver cancers, as it does not engage liver and renal functions, i.e. nanoparticles are not metabolized and not excreted by kidney. A phase I/II trial has been implemented for the treatment of hepatocellular carcinoma and liver metastasis. […]

The post 2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers first appeared on Nano Publications.]]>

Authors

Chajon E.1, Pracht M.1, De Baere T.2, Nguyen F.2, Bronowicki J.-P.3, Vendrely V.4, Baumann A.-S.5,
Croisé-Laurent V.3, Deutsch E.2
1 – Radiation oncology, Centre Eugene – Marquis, Rennes, FR
2 – Radiation oncology, Institut Gustave Roussy, Villejuif, FR
3 – Hepatology and Gastroenterology, Hôpital de Brabois, Vandoeuvre Les Nancy, FR
4 – Radiotherapy, Groupe Hospitalier Sud – Hôpital Haut-Lévêque, Pessac, FR
5 – Radiotherapy, Institut de Cancérologie de Lorraine, Nancy, FR

Summary

The physical mode of action of NBTXR3 may represent a breakthrough approach for the local treatment of liver cancers, as it does not engage liver and renal functions, i.e. nanoparticles are not metabolized and not excreted by kidney. A phase I/II trial has been implemented for the treatment of hepatocellular carcinoma and liver metastasis [NCT02721056].

At the 2018 Gastrointestinal Cancers Symposium (also known as ASCO-GI) at San Francisco (CA, USA), Dr. Chajon presented preliminary results on this study.

Overall, the injection of NBTXR3 was safe and well tolerated at these levels. Patients received the planned RT. No DLT occurred. Enrollment is now opened at the 22% level. NBTXR3 shows promising results in terms of safety and antitumor activity and is also currently evaluated in other six clinical studies.

The post 2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers first appeared on Nano Publications.]]> https://bibliography.nanobiotix.com/2018-asco-gi-a-phase-i-ii-trial-of-nbtxr3-nanoparticles-activated-by-sbrt-in-the-treatment-of-liver-cancers/feed/ 0 2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer https://bibliography.nanobiotix.com/2018-multidisciplinary-h-n-nbtxr3-for-head-and-neck-cancer/ https://bibliography.nanobiotix.com/2018-multidisciplinary-h-n-nbtxr3-for-head-and-neck-cancer/#respond Tue, 05 Jun 2018 16:00:22 +0000 http://bibliography.nanobiotix.com/?p=1435 NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau. […]

The post 2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer first appeared on Nano Publications.]]>

Authors

Le Tourneau C.1, Calugaru V.1, Thariat J.O.2, Florescu C.3, Mirabel X.4, Jegoux F.5, Jouffroy T.1, Rodriguez J.1, Hoffmann C.1, Dodger B.6, Moreno Garcia V.7, Dimitriu M.8, Levy L.8, and Calvo E.6
1 – Institut Curie, Paris, France
2 – Centre Antoine-Lacassagne, Nice, France
3 – Centre Francois Baclesse, Caen, France
4 – Centre Oscar Lambret, Lille, France
5 – Centre Hospitalier Universitaire de Rennes, Rennes, FL, France
6 – START Madrid, Madrid, Spain
7 – Hospital Fundacio´n Jimenez Diaz, Madrid, Spain
8 – Nanobiotix, Paris, France

Summary

NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer [NCT01946867]. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau.

So far, patients treated in phase I showed good local and systemic tolerance to the product up to the highest dose level and received radiotherapy as planned, confirming a very good local safety profile. Regarding the patients, the durability of response so far is superior to 13 months, with some patients at 16 and 22 months follow-up without recurrence.

NBTXR3 nanoparticles constitute a rising hope for head and neck cancer patients as it could lead to a decrease in the long-term adverse effects of RT and an improvement in quality of life, associated with strong locoregional control.

The post 2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer first appeared on Nano Publications.]]> https://bibliography.nanobiotix.com/2018-multidisciplinary-h-n-nbtxr3-for-head-and-neck-cancer/feed/ 0